tiprankstipranks
Trending News
More News >
Eris Lifesciences Ltd (IN:ERIS)
:ERIS
India Market
Advertisement

Eris Lifesciences Ltd (ERIS) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

ERIS Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Eris
Lifesciences Ltd
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ERIS Stock 12 Month Forecast

Average Price Target

₹1,880.00
▲(5.96%Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Eris Lifesciences Ltd in the last 3 months. The average price target is ₹1,880.00 with a high forecast of ₹1,880.00 and a low forecast of ₹1,880.00. The average price target represents a 5.96% change from the last price of ₹1,774.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"885":"₹885","1134":"₹1,134","1383":"₹1,383","1632":"₹1,632","1881":"₹1,881"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1880,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.88K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1880,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.88K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1880,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.88K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[885,1134,1383,1632,1881],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1666.65,1683.0615384615385,1699.473076923077,1715.8846153846155,1732.2961538461539,1748.7076923076925,1765.1192307692309,1781.5307692307692,1797.9423076923076,1814.3538461538462,1830.7653846153846,1847.1769230769232,1863.5884615384616,{"y":1880,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1666.65,1683.0615384615385,1699.473076923077,1715.8846153846155,1732.2961538461539,1748.7076923076925,1765.1192307692309,1781.5307692307692,1797.9423076923076,1814.3538461538462,1830.7653846153846,1847.1769230769232,1863.5884615384616,{"y":1880,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1666.65,1683.0615384615385,1699.473076923077,1715.8846153846155,1732.2961538461539,1748.7076923076925,1765.1192307692309,1781.5307692307692,1797.9423076923076,1814.3538461538462,1830.7653846153846,1847.1769230769232,1863.5884615384616,{"y":1880,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":886.57,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":911.03,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1044.32,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1112.73,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1411.04,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1315.53,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1313.54,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1452.45,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1323.98,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1221.46,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1180.7,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1180.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1666.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹1,880Average Price Target₹1,880Lowest Price Target₹1,880
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on IN:ERIS
TipRanks AITipRanks
Not Ranked
TipRanks
₹1,926
Buy
8.56%
Upside
07/08/25
Eris Lifesciences Ltd scores well due to strong financial performance and positive technical indicators. However, its high P/E ratio and low dividend yield suggest potential overvaluation, weighing down the overall score.
Investec
₹1,880
Buy
5.96%
Upside
Reiterated
05/18/25
Investec Reiterates Buy Rating on Eris Lifesciences (ERIS:IN)Investec analyst Anshuman Gupta reiterated a Buy rating and INR1,880.00 price target on Eris Lifesciences (ERIS:IN).
Macquarie
₹1,680
Buy
-5.31%
Downside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Eris Lifesciences (ERIS:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,680.00 price target on Eris Lifesciences (ERIS:IN).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on IN:ERIS
TipRanks AITipRanks
Not Ranked
TipRanks
₹1,926
Buy
8.56%
Upside
07/08/25
Eris Lifesciences Ltd scores well due to strong financial performance and positive technical indicators. However, its high P/E ratio and low dividend yield suggest potential overvaluation, weighing down the overall score.
Investec
₹1,880
Buy
5.96%
Upside
Reiterated
05/18/25
Investec Reiterates Buy Rating on Eris Lifesciences (ERIS:IN)Investec analyst Anshuman Gupta reiterated a Buy rating and INR1,880.00 price target on Eris Lifesciences (ERIS:IN).
Macquarie
₹1,680
Buy
-5.31%
Downside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Eris Lifesciences (ERIS:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,680.00 price target on Eris Lifesciences (ERIS:IN).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eris Lifesciences Ltd

1 Month
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+21.30%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +21.30% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+21.50%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +21.50% per trade.
1 Year
Success Rate
1/1 ratings generated profit
100%
Average Return
+26.40%
reiterated a buy rating 4 months ago
Copying Kunal Dhamesha's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.40% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+25.70%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ERIS Analyst Recommendation Trends

Rating
Mar 25
Jul 25
Strong Buy
0
0
Buy
1
6
Hold
0
0
Sell
0
0
Strong Sell
0
0
total
1
6
In the current month, ERIS has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ERIS average Analyst price target in the past 3 months is 1,880.00.
Each month's total comprises the sum of three months' worth of ratings.

ERIS Financial Forecast

ERIS Earnings Forecast

Next quarter’s earnings estimate for ERIS is ₹8.52 with a range of ₹8.00 to ₹9.00. The previous quarter’s EPS was ₹6.90. ERIS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.00% of the time in the same period. In the last calendar year ERIS has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ERIS is ₹8.52 with a range of ₹8.00 to ₹9.00. The previous quarter’s EPS was ₹6.90. ERIS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 40.00% of the time in the same period. In the last calendar year ERIS has Preformed in-line its overall industry.

ERIS Sales Forecast

Next quarter’s sales forecast for ERIS is ₹8.06B with a range of ₹7.61B to ₹9.32B. The previous quarter’s sales results were ₹7.05B. ERIS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 55.38% of the time in the same period. In the last calendar year ERIS has Outperformed its overall industry.
Next quarter’s sales forecast for ERIS is ₹8.06B with a range of ₹7.61B to ₹9.32B. The previous quarter’s sales results were ₹7.05B. ERIS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 55.38% of the time in the same period. In the last calendar year ERIS has Outperformed its overall industry.

ERIS Stock Forecast FAQ

What is IN:ERIS’s average 12-month price target, according to analysts?
Based on analyst ratings, Eris Lifesciences Ltd’s 12-month average price target is 1,880.00.
    What is IN:ERIS’s upside potential, based on the analysts’ average price target?
    Eris Lifesciences Ltd has 5.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Eris Lifesciences Ltd a Buy, Sell or Hold?
          Eris Lifesciences Ltd has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Eris Lifesciences Ltd’s share price target?
            The average share price target for Eris Lifesciences Ltd is 1,880.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹1,880.00 ,and the lowest forecast is ₹1,880.00. The average share price target represents 5.96% Increase from the current price of ₹1,774.2.
              What do analysts say about Eris Lifesciences Ltd?
              Eris Lifesciences Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Eris Lifesciences Ltd?
                To buy shares of IN:ERIS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis